Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Beta Bionics received FDA clearance for Mint, a two-piece reusable and disposable patch pump that never requires recharging and is controlled via iOS and Android smartphones. - The company unveiled 3D Intelligence, a next-generation insulin dosing algorithm submitted to the FDA via 510(k) with Original, Optimized and Conservative clinician-selectable experiences. - Full U.S. commercialization of Mint is expected in Q1 2027, with manufacturing capacity for at least 1.5 million disposable units during 2027. - Beta Bionics lowered full-year 2026 revenue guidance to $121 million-$126 million, citing up to $10 million in potential Q4 deferral as patients await Mint.
- Beta Bionics announced plans to commercialize its Mint patch pump by the end of Q2 2027, pending FDA clearance of its 510(k) application. - The device will feature the company's proprietary interoperable automated glycemic controller (iAGC), the first fully adaptive insulin dosing algorithm approved in the United States. - Mint will compete directly with Insulet's patch pumps by offering similar size and three-day wear time, but with a unique two-piece reusable and disposable architecture. - The company expects sufficient manufacturing capacity at launch and plans exclusive pharmacy channel distribution leveraging existing iLet market access agreements.
- Insulet Corporation has issued a voluntary recall of specific lots of Omnipod 5 insulin patch pumps due to small tears in internal tubing that can cause insulin leakage inside the device rather than delivery to the body. - The company has reported 18 serious adverse events associated with high blood glucose levels, including hospitalizations and diabetic ketoacidosis, though no deaths have been reported. - The recall affects approximately 1.5% of Insulet's annual global Omnipod 5 production, with the company expecting to incur up to $40 million in associated costs this year. - Insulet is providing free replacement pods to affected customers and has implemented manufacturing process updates and quality control improvements following an investigation.
- Luna Health raised $23.6 million in Series A funding led by Vensana Capital to develop the world's smallest insulin patch pump with a fully closed-loop algorithm for nighttime glucose control. - The innovative patch pump targets the vast majority of people with Type 1 and Type 2 diabetes who rely on insulin pens, delivering automated rapid-acting insulin during sleep when over 80% of glucose improvement occurs. - The company was founded by healthcare technology executives with diabetes experience, including former Bigfoot Biomedical leaders and Beta Bionics CEO Sean Saint. - Luna's approach focuses specifically on nighttime automation to reduce complexity and costs compared to traditional 24/7 pump therapy, making automated insulin delivery accessible to millions worldwide.
- Beta Bionics announced plans to integrate its iLet Bionic Pancreas automated insulin delivery system with Abbott's future dual glucose-ketone sensor in the U.S. - The iLet represents the first and only automated insulin delivery system that makes 100% of insulin dosing decisions automatically without requiring carb counting or manual calculations. - This collaboration extends the existing partnership between Beta Bionics and Abbott, building on the current integration with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor. - The integration aims to enhance real-time decision-making support for people living with diabetes through advanced automated insulin delivery technology.
- Insulet shared real-world glycemic outcomes data from over 23,000 people with type 2 diabetes using the Omnipod 5 automated insulin delivery system in the United States. - New analysis from the SECURE-T2D pivotal trial demonstrated that Omnipod 5 significantly reduced diabetes distress in adults with type 2 diabetes over 13 weeks. - More than 30% of new patient starts in Q1 2025 were people with type 2 diabetes, reflecting growing adoption since FDA expanded indication in August 2024. - The company is advancing development of next-generation hybrid closed-loop and fully closed-loop systems, with plans to begin second EVOLUTION studies for type 2 diabetes in the second half of 2025.
- Medtronic has submitted 510(k) applications to the FDA for its MiniMed 780G pump as an alternate controller enabled device and its SmartGuard algorithm as an interoperable automated glycemic controller. - The regulatory submissions mark a significant milestone in Medtronic's collaboration with Abbott, which will supply a continuous glucose monitoring sensor based on its most advanced CGM platform. - If cleared, the interoperable system would represent a strategic shift for Medtronic, which previously focused on pairing only its own devices, now offering patients more device integration options.
- The iLet Bionic Pancreas automated insulin delivery system achieved target glucose levels in 97% of adults with type 1 diabetes, with no significant differences between primary care and endocrinology settings. - Researchers found the simplified device setup and management worked equally well via telehealth or in-person visits, potentially expanding access to advanced diabetes technology beyond specialty care. - The study demonstrated that primary care patients experienced greater improvements in hypoglycemia metrics compared to those under endocrinologist care, suggesting broader implementation possibilities.
• Beta Bionics has launched the integration of its iLet bionic pancreas with Abbott's FreeStyle Libre 3 Plus CGM, streamlining diabetes management. • The iLet system, cleared by the FDA in May 2023, simplifies insulin delivery by eliminating carb counting and correction calculations, requiring only the user's weight as input. • Abbott's FreeStyle Libre 3 Plus CGM provides minute-by-minute glucose readings to the iLet system, enhancing the accuracy of insulin dose calculations. • This integration offers a new option for managing type 1 diabetes, with both iLet and FreeStyle Libre 3 Plus available through pharmacy channels and durable medical equipment providers.
